Basel/Switzerland and Bridgewater NJ/USA, 27 August 2007 Speedel (Swiss:SPPN.SW - News) today welcomed the announcement that Novartis has received European Union approval of SPP100 (Rasilez[i]) the first major innovation in high blood pressure treatment for more than a decade. Nearly half of all adults in Europe's largest countries, such as Germany, Italy and the UK, suffer from this potentially life-threatening condition.
